科学技术顾问委员会由IHAI协作的相关医疗和科研机构、大专院校、产业园区、行业、企业推荐的100位专家组成国内外专家资源库。 根据IHCA提供的产业评估、技术咨询，标准认证、科研立项、产品监制、协作研究等项目需要， 由科学顾问委员会主席与专业学术组织共同召开科学顾问委员会会议
科学技术顾问委员会
SCIENCE AND TECHNOLOGY ADVISORY COMMITTEE
Technology Advisory Committee consists of 100 experts recommended by IHAI's relevant medical and scientific research institutions, universities, industrial parks, industries, and enterprises. According to the needs of IHI's industrial assessment, technical consultation, standard certification, research project, product supervision, collaborative research, etc., the chairman of the scientific advisory committee and the professional academic organization jointly hold the meeting of the scientific advisory committee.
科学顾问委员会主席
Chairman of the Scientific Advisory Board
CHAIRMAN OF THE SCIENTIFIC ADVISORY BOARD
D．G．Brikmayer ，Ph.D., Professor
George Birkmayer医学博士、化学博士、教授, 1969年在维也纳大学进修生物化学博士学位，1973年在德国慕尼黑大学获得细胞生物学授课教授资格，1979年在慕尼黑大学获得医学博士学位，1982年开始就职于奥地利格拉茨大学医学化学教授，1988年开始就职于慕尼黑大学细胞生物学副教授。他是150多种科学出版物的作者，纽约、旧金山、北京、广州和西安（中国）等地大学的客座教授，纽约国际肿瘤标志物肿瘤学会（IATMO）主席，新科学研究院院士，美国营养学院院士。抗衰老NADH治疗效果的发现者。 美国医学促进学会年度Denham Harman讲座嘉宾。自2010年起担任国际靶向治疗学会名誉主席。他在肿瘤学、神经病学和抗衰老医学研究方面进行过多次全球性的讲座，研究成果获得多国赞誉，他是多个行业的资深权威，维也纳帕金森病研究所所长、国际肿瘤标志杂志主编、世界抗衰老药物NADH权威专家。
George Birkmayer, MD, Ph.D., Professor, Ph.D. in Biochemistry at the University of Vienna in 1969, Professor of Cell Biology at the University of Munich, Germany in 1973, Doctor of Medicine at the University of Munich in 1979, and in 1982 Professor of Medical Chemistry at the University of Graz, Austria, began working as an associate professor of cell biology at the University of Munich in 1988. He is the author of more than 150 scientific publications, visiting professors at universities in New York, San Francisco, Beijing, Guangzhou, and Xi'an (China), president of the New York International Society for Oncology and Oncology (IATMO), Fellow of the New Science Institute, and American Nutrition. Academician of the Academy. The discoverer of anti-aging NADH treatment effects. Distinguished guest of the American Society for the Advancement of Medicine, Denham Harman. Since 2010, he has served as Honorary President of the International Society for Targeted Therapy. He has lectured many times in oncology, neurology and anti-aging medical research. His research has won many national praises. He is a senior authority in many industries. He is the director of the Vienna Parkinson's Disease Research Institute and the International Journal of Cancer Markers. Editor-in-chief, the world's leading expert in anti-aging drugs NADH.
JR Zhang，Ph.D, MD,
张积仁，博士，南方医科大学珠江医院原肿瘤中心科主任，
教授、主任医师，博士生导师
广东省靶向肿瘤干预与防控研究院院长
1993年被授予"全国百名医学中青年科技之星"荣誉称号，并享受政府津贴，1996入选了国家百千万人才工程一二层次，被广东省选为广东省生物技术学术带头人，1999年评为优秀归国人员。承担国家自然基金，广东省重大课题项8项，并参加1项国家863课题的研究。2000年被邀为奥地利维也纳大学Birkmayer研究所和香港大学客座教授。并与加拿大渥太华大学放射肿瘤部，美国加利福尼亚大学Davis肿瘤中心，英国剑桥大学Wolfson学院建立研究生培养和协作交流关系。担任第一届中国医疗保健国际交流促进会分子保健分会主任委员 、中国抗癌协会肿瘤微创治疗专业委员会资深顾问 、香港中华冷冻学会主席、中国生物医学工程学会肿瘤靶向治疗技术学会主任 委员 ，全国卫生产业企业管理协会预防医疗分会副理事长兼秘书长，全国老年保健协会甲状腺结节肿瘤风险防控委员会主任委员，曾任第1-7届中国靶向治疗大会主席，第1-4届国际靶向治疗大会主席，第十四届国际冷冻大会主席，第1-2届国际慢病预防医疗联盟大会主席。创建提出TE-PEMIC预防医疗体系，是TE-PEMIC慢病绿色预防医疗体系创始人，被评为全国卫生健康技术推广传承应用项目（慢病分子检测与防控技术）传承人。主要致力于:肿瘤靶向防控和抗衰老研究。创建提出TE-PEMIC预防医疗体系，被誉为预防医疗带头人
Jiren Zhang, male, Doctor, Director, professor, chief physician and doctoral supervisor of Primary Cancer Center, Zhujiang Hospital, Southern Medical University. In 1993, he was awarded the honorary title of "National One Hundred Medical Young and Middle-aged Science and Technology Star" and enjoyed government subsidies. In 1996, he was selected as the National one or two levels of the Ten Million Talents Project, and was selected as the academic leader of Biotechnology in Guangdong Province. In 1999, he was rated as an excellent returnee. It undertakes 8 major projects of the National Nature Foundation and Guangdong Province, and participates in 1 national 863 research project. In 2000, he was invited as a visiting professor at the Birkmayer Institute of the University of Vienna and the University of Hong Kong. In addition, the University of Ottawa, Canada, Department of Radiation Oncology, the University of California Davis Cancer Center, the United States, the University of Cambridge Wolfson College to establish graduate training and collaborative exchange relations. He served as the Chairman of the Molecular Health Branch of the first China Association for the Promotion of International Healthcare Exchanges, the senior consultant of the Minimally Invasive Tumor Therapy Professional Committee of the Chinese Anti-Cancer Association, the chairman of the Hong Kong Chinese Cryotherapy Society, and the chairman of the Tumor Targeted Therapy Technology Society of the Chinese Biomedical Engineering Society. Vice Chairman and Secretary-General of the Preventive Medicine Branch of the National Health Industry Enterprise Management Association, Chairman of the Thyroid Nodule Tumor Risk Prevention Committee of the National Geriatric Health Care Association, Chairman of the 1st to 7th China Targeted Therapy Congress, Chairman of the 1st to 4th International Targeted Therapy Congress, Chairman of the 14th International Refrigeration Congress, President of the 1-2 Congress of the International Alliance for the Prevention of Chronic Diseases. He is the founder of TE-PEMIC Green chronic disease prevention medical system, and was named the inheritor of the National Health Technology Promotion Inheritance and Application Project (Chronic disease molecular Detection and Prevention Technology). Mainly devoted to: tumor targeted prevention and control and anti-aging research. He created and put forward TE-PEMIC preventive medical system and was known as the leader of preventive medical treatment
Dr. Elke Schwesig-Seebach医学博士
先后就读于美国圣地亚哥大学和德国汉堡大学，于1994年获得医学博士
1992年5月–1992年10月，英国萨默塞特，汤顿萨默塞特医院，心内科，医生；1993年7月–1993年11月，土耳其伊斯坦布尔,卡帕大学医院,胸腔医学科，医生；1994年4月–1994年10月，印度孟买，阿里汗王子医院，神经科，医生；1994年10月–1996年12月，德国汉堡，汉堡大学医院，神经内科，专注于癫痫和帕金森病以及颅/脑创伤和内外科问题引起的神经系统并发症 , 从事临床医疗工作；1997年1月–2002年12月，德国慕尼黑，罗兰贝格管理咨询公司，高级医学顾问，从事医疗咨询管理工作；2002年1月–2005年12月，德国慕尼黑，诊疗医院，董事会成员，从事医疗咨询管理工作；2005年2月–至今，德国慕尼黑，Duale Medizin（杜尔勒医院），创始人，专门致力于内分泌学和生物同源型荷尔蒙治疗，从事医疗及医院管理工作。
In 3/2015 she published her state-of the art book “Integrative Medicine in Oncology- a holistic approach” which is already translated into Chinese language.；In 10/2019 her second book Bio-identic Hormones in der Substitutional Therapy- the management of the hormonal orchestra of ovaries, testis, adrenals and thyroid” was published in Germany as well as in China；The clinical concept of Duale Medizin in Germany became so popular, that it attracted an international patient clientele and Dr. Schwesig-Seebach is consulting several hospital projects in China as well as in Vietnam；2018 Dr. Schwesig-Seebach reached a Chinese working permission as clinical doctor and teaching professor。
